19 Jul 2026

CRC Research Update — July 19, 2026

Creator: The CRC Digest
Published: 2026-07-19T11:42:32Z

Today's colorectal cancer research highlights

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

TRIAL DATA
BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer
This randomized study evaluated targeted therapy combinations specifically for patients with BRAF V600E mutations, a subtype associated with poorer outcomes. (Annals of Oncology)
SCREENING
Systematic review and meta-analysis quantifies sensitivity and specificity of fecal immunochemical testing and colonoscopy for colorectal cancer screening
Researchers analyzed multiple studies to estimate the accuracy of two major screening tests in asymptomatic average-risk adults. (Preventive Medicine Reports)
TREATMENT
Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer
A multicentre study followed patients treated with bevacizumab combined with chemoradiation before surgery for locally advanced rectal cancer. (Clinical Colorectal Cancer)
RESEARCH
Single-section PMS2/MSH6 double immunohistochemistry shows promise as screening tool for mismatch repair deficiency
A study of 794 colorectal and endometrial cancer cases evaluated whether a single-section test could accurately identify deficient mismatch repair (dMMR) status. (Human Pathology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

First Nations people in Ontario experience higher colon cancer incidence at younger ages
New evidence shows registered First Nations people have higher colon cancer incidence at younger ages and poorer survival after breast, cervical, and colon cancer diagnoses than other Ontario residents. (The Lancet Oncology)
Case-control study compares metabolic and laboratory biomarkers in early-onset versus late-onset colorectal cancer
Researchers used a large US database to compare metabolic, inflammatory, and laboratory abnormalities between patients diagnosed at ages 18-49 versus 50-75. (Cancers)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Oncogenic KRAS drives xCT upregulation and ferroptosis evasion through CCDC6 degradation
Researchers identified a mechanism by which KRAS mutations promote tumor cell survival by degrading the CCDC6 tumor suppressor, leading to increased xCT expression and protection from oxidative stress. (Apoptosis)

Stay informed, and remember that research advances one step at a time.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest